Kidney Transplant Rejection – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Kidney Transplant Rejection – Pipeline Review, H1 2017’, provides an overview of the Kidney Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection

The report reviews pipeline therapeutics for Kidney Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Kidney Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Angion Biomedica Corp

Apellis Pharmaceuticals Inc

Astellas Pharma Inc

Biogen Inc

Catalyst Biosciences Inc

Corline Biomedical AB

CSL Ltd

GlaxoSmithKline Plc

Grifols SA

Hansa Medical AB

Kyowa Hakko Kirin Co Ltd

Magnus Life Ltd

Noorik Biopharmaceuticals AG

Novartis AG

Opsona Therapeutics Ltd

OSE Immunotherapeutics

Pharmicell Co Ltd

Pharming Group NV

Prolong Pharmaceuticals LLC

Quark Pharmaceuticals Inc

Shire Plc

Tiziana Life Sciences Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Kidney Transplant Rejection - Overview 7

Kidney Transplant Rejection - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Kidney Transplant Rejection - Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Kidney Transplant Rejection - Companies Involved in Therapeutics Development 24

Amgen Inc 24

Angion Biomedica Corp 24

Apellis Pharmaceuticals Inc 25

Astellas Pharma Inc 25

Biogen Inc 26

Catalyst Biosciences Inc 26

Corline Biomedical AB 27

CSL Ltd 27

GlaxoSmithKline Plc 28

Grifols SA 28

Hansa Medical AB 29

Kyowa Hakko Kirin Co Ltd 29

Magnus Life Ltd 30

Noorik Biopharmaceuticals AG 30

Novartis AG 31

Opsona Therapeutics Ltd 31

OSE Immunotherapeutics 32

Pharmicell Co Ltd 32

Pharming Group NV 33

Prolong Pharmaceuticals LLC 33

Quark Pharmaceuticals Inc 34

Shire Plc 34

Tiziana Life Sciences Plc 35

Kidney Transplant Rejection - Drug Profiles 36

albumin (human) - Drug Profile 36

ambrisentan - Drug Profile 37

AMY-101 - Drug Profile 38

APL-2 - Drug Profile 40

AS-2521780 - Drug Profile 43

ASP-0028 - Drug Profile 44

basiliximab biobetter - Drug Profile 45

BB-3 - Drug Profile 46

belimumab - Drug Profile 50

bleselumab - Drug Profile 57

C1 esterase inhibitor (human) - Drug Profile 59

C1 esterase inhibitor (human) - Drug Profile 64

C1 esterase inhibitor (recombinant) - Drug Profile 67

carfilzomib - Drug Profile 74

CB-2782 - Drug Profile 86

Cellgram for Kidney Transplant Rejection - Drug Profile 87

Cellular Immunotherapy for Kidney Transplantation - Drug Profile 88

Cellular Immunotherapy for Kidney Transplantation - Drug Profile 89

Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 90

CFZ-533 - Drug Profile 91

foralumab - Drug Profile 93

FR-104 - Drug Profile 95

FX-06 - Drug Profile 98

GSK-1070806 - Drug Profile 100

HBI-002 - Drug Profile 101

HBI-137 - Drug Profile 102

lefluonomide - Drug Profile 103

Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 104

Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile 106

MRX-109 - Drug Profile 107

OPN-305 - Drug Profile 108

QPI-1002 - Drug Profile 111

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 114

Renaparin - Drug Profile 119

rituximab - Drug Profile 120

Sanguinate - Drug Profile 126

tiomolibdate diammonium - Drug Profile 129

TNT-009 - Drug Profile 130

Kidney Transplant Rejection - Dormant Projects 133

Kidney Transplant Rejection - Discontinued Products 135

Kidney Transplant Rejection - Product Development Milestones 136

Featured News & Press Releases 136

Appendix 145

Methodology 145

Coverage 145

Secondary Research 145

Primary Research 145

Expert Panel Validation 145

Contact Us 145

Disclaimer 146

List of Tables

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Kidney Transplant Rejection – Pipeline by Amgen Inc, H1 2017

Kidney Transplant Rejection – Pipeline by Angion Biomedica Corp, H1 2017

Kidney Transplant Rejection – Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc, H1 2017

Kidney Transplant Rejection – Pipeline by Biogen Inc, H1 2017

Kidney Transplant Rejection – Pipeline by Catalyst Biosciences Inc, H1 2017

Kidney Transplant Rejection – Pipeline by Corline Biomedical AB, H1 2017

Kidney Transplant Rejection – Pipeline by CSL Ltd, H1 2017

Kidney Transplant Rejection – Pipeline by GlaxoSmithKline Plc, H1 2017

Kidney Transplant Rejection – Pipeline by Grifols SA, H1 2017

Kidney Transplant Rejection – Pipeline by Hansa Medical AB, H1 2017

Kidney Transplant Rejection – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Kidney Transplant Rejection – Pipeline by Magnus Life Ltd, H1 2017

Kidney Transplant Rejection – Pipeline by Noorik Biopharmaceuticals AG, H1 2017

Kidney Transplant Rejection – Pipeline by Novartis AG, H1 2017

Kidney Transplant Rejection – Pipeline by Opsona Therapeutics Ltd, H1 2017

Kidney Transplant Rejection – Pipeline by OSE Immunotherapeutics, H1 2017

Kidney Transplant Rejection – Pipeline by Pharmicell Co Ltd, H1 2017

Kidney Transplant Rejection – Pipeline by Pharming Group NV, H1 2017

Kidney Transplant Rejection – Pipeline by Prolong Pharmaceuticals LLC, H1 2017

Kidney Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc, H1 2017

Kidney Transplant Rejection – Pipeline by Shire Plc, H1 2017

Kidney Transplant Rejection – Pipeline by Tiziana Life Sciences Plc, H1 2017

Kidney Transplant Rejection – Dormant Projects, H1 2017

Kidney Transplant Rejection – Dormant Projects, H1 2017 (Contd..1), H1 2017

Kidney Transplant Rejection – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports